Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL321302 | 0.96 | THRB (0.39) | THRBMGAMGAASIMGAM2 | |
| SCHEMBL10532061 | 0.83 | FFAR1 (0.42) | TSHR | |
| SCHEMBL10779438 | 0.81 | LMNA (0.44) | MGAMGAASIMGAM2LDHA | |
| SCHEMBL6270772 | 0.77 | TSHR (0.38) | MGAMGAASIMGAM2LDHA | |
| SCHEMBL8195362 | 0.77 | TSHR (0.38) | MGAMGAASIMGAM2LDHA | |
| SCHEMBL27545539 | 0.77 | EGLN1 (0.42) | THRBFFAR3EGLN1TSHR | |
| SCHEMBL17501746 | 0.77 | THRB (0.50) | THRBMGAMGAASIMGAM2 | |
| SCHEMBL22630891 | 0.76 | MGAM (0.31) | MGAMGAASIMGAM2 | |
| Butane SCHEMBL10826497 | 0.75 | ALOX15 (0.36) | LDHASRRFFAR3TSHR | |
| SCHEMBL783625 | 0.75 | THRB (0.48) | THRBMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116200183-B | High-efficiency variable-viscosity fracturing fluid for deep coal bed gas development and integrated construction method | 四川申和新材料科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-114890945-B | Method for synthesizing nadifloxacin intermediate | 大连万福制药有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116200183-A | High-efficiency variable-viscosity fracturing fluid for deep coal bed gas development and integrated construction method | 四川申和新材料科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| EP-0086723-B1 | SUBSTITUTED PYRIMIDONES AND THEIR SALTS, THEIR PREPARATION, THEIR APPLICATION AS MEDICAMENTS, COMPOSITIONS CONTAINING THEM AND INTERMEDIATES OBTAINED | ROUSSEL-UCLAF (FR) | 1987-04-22 | — | — | EP | claimed |
| CN-115433124-B | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-116200183-B | High-efficiency variable-viscosity fracturing fluid for deep coal bed gas development and integrated construction method | 四川申和新材料科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11925690-B2 | Bifunctional molecules for targeting Rpn11 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-12 | — | — | US | disclosed |
| WO-2024022487-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20240024236-A1 | EMULSION COMPRISING SIZE-CONTROLLED DROPLETS | CALYXIA (FR) | 2024-01-25 | — | — | US | disclosed |
| WO-2023208173-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
| CN-111356690-B | Benzamide derivative compound, preparation method thereof, and pharmaceutical composition for preventing or treating inflammatory disease | 首尔大学校产学协力团 | 2023-09-29 | — | — | CN | disclosed |
| CN-116685584-A | N- (2, 3-dihydro-1, 4-benzoxazin-4-yl) -3-isopropyl-7- (2, 3, 5-trifluorophenyl) benzothiophene-2-carboxamide derivatives and similar compounds for the treatment of heartworm infections | 礼蓝动物保健有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-0184384-A1 | Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them | PFIZER INC. (US) | 1986-06-11 | — | — | EP | disclosed |
| US-4537886-A | β-lactam antibacterial agents and compositions containing them | BEECHAM GROUP P.L.C. (GB) | 1985-08-27 | — | — | US | disclosed |
| US-4482557-A | 3-Substituted-2-oxo-tetrahydro-pyrrol[1,2-a]pyrimidines having digitalis-like activity | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1984-11-13 | — | — | US | disclosed |
| EP-0090656-A1 | Penicillins, a process for the preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1983-10-05 | — | — | EP | disclosed |
| US-4404205-A | CARDIOTONIC AGENTS; ANGINA PECTORIS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1983-09-13 | — | — | US | disclosed |
| US-4367229-A | 3-Substituted-tetrahydro-pyrrolo[1,2-a]pyrimidines and pharmaceutical compositions | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1983-01-04 | — | — | US | disclosed |
| US-4046577-A | PHOTOREACTIVE COMPOSITIONS COMPRISING POLYMERS CONTAINING ALKOXYAROMATIC GLYOXY GROUPS | THE RICHARDSON COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-3984548-A | Substituted pyrido[1,2,3,-de]-1,4-benzoxazines as bactericides | RIKER LABORATORIES, INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11925690-B2 | Bifunctional molecules for targeting Rpn11 | RPN1, RPP30, UBQLN1 | THRB 4451/4885MGAM 3403/4885GAA 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.